Indeed, the optimal inter-observer and inter-antibody agreement of PTEN assessment, reported in the context of a prospective cohort of BC patients enrolled in a phase III randomized trial [29], appears reassuring and encourages further efforts in the context of well-designed and well-conducted biomarker-driven trials. Here, PTEN is linked to breast cancer.